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Abstract
Background: High grade serous ovarian cancer (HGSOC) is among the deadliest human cancers and its prognosis
remains extremely poor. Tumor heterogeneity and rapid acquisition of resistance to conventional chemotherapeutic
approaches strongly contribute to poor outcome of patients. The clinical landscape of HGSOC has been radically
transformed since the advent of targeted therapies in the last decade. Nevertheless, the lack of predictive
biomarkers informing on the differential clinical benefit in select subgroups, and allowing patient-centric
approaches, currently limits the efficacy of these novel therapies. Thus, rational selection of the best possible
treatment for each patient represents a clinical priority in order to improve outcome, while limiting undesirable
effects.
Main body: In this review, we describe the state of the art and the unmet needs in HGSOC management, illustrate
the treatment options that are available and the biomarkers that are currently employed to orient clinical decisions.
We also describe the ongoing clinical trials that are testing new therapeutic approaches for HGSOC. Next, we
introduce the organoid technology as a promising, expanding strategy to study cancer and to develop
personalized therapeutic approaches. In particular, we discuss recent studies that have characterized the
translational potential of Patient’s Derived Organoids (PDOs) to inform on drug sensitivity of HGSOC patients.
Conclusions: PDOs can predict the response of patients to treatments and may therefore guide therapeutic
decisions. Although preliminary results appear encouraging, organoids still need to be generated and expanded
efficiently to enable drug screening in a clinically meaningful time window. A new generation of clinical trials based
on the organoid technology should guarantee tailored approaches to ovarian cancer management, as it is now
clear that the one-size-fits-all approach cannot lead to efficient and meaningful therapeutic advancements.
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Background
The overall survival of patients with ovarian cancer (OC)
had not substantially changed for several decades, mainly
due to the lack of early diagnosis coupled with frequent
acquisition of resistance to therapeutic treatments [1, 2].
Nevertheless, recent progress in traditional and novel
therapeutic strategies have led to a significant improve-
ment in patient’s outcome especially for the high grade
serous histotype (HGSOC), which is the most common
and most malignant among the OC subtypes [3–5]. In
particular, several treatment options have become avail-
able in the past 5 years, both for frontline and recurrent
disease settings.
Decisions regarding the best treatment option for
each individual patient do not always have an obvious
“optimal choice”, due to a number of variables that
are not always easy to decipher. First, both the type
and the timing of treatment(s) have to be considered.
Moreover, while algorithms based on patient’s charac-
teristics and biological factors are necessary, they are
not diagnostically exhaustive. Lastly, the identification
of successful therapies is also hampered by the high
level of complexity and genetic heterogeneity existing
even within single tumor types. With more thera-
peutic options being available, the identification of
biological markers and/or experimental models that
are able to predict treatment response has progres-
sively become a clinical priority.
In this scenario, an emerging technology that holds
promise of significantly impacting the clinical manage-
ment of patients in the near future is represented by
patient-derived Organoids (PDOs). Indeed, elegant stud-
ies carried out in the past 2–3 years have clearly indi-
cated that HGSOC PDOs have the potential to faithfully
reproduce many of the challenging characteristics of the
tumor from which they derive in a reasonable time
frame and at sustainable costs [6–10]. This technology
may offer the possibility of attaining truly personalized
drug-based therapy. On this basis, it is conceivable that
PDOs could be introduced as a clinical test to guide the
selection of therapeutic treatments and to improve man-
agement of HGSOC patients in the near future.
State of the art and unmet needs in ovarian
cancer clinical management
Treatment options and predictive biomarkers
The current treatment options for advanced stage and
recurrent HGSOC according to ESMO and NCCN rec-
ommendations [11, 12] are summarized in Fig. 1.
Treating HGSOC has become an increasingly complex
chess game in which clinicians should be fully aware of
the consequences that each move implies. Identifying tu-
mors that will respond to the available therapies in that
precise moment of the disease is an emerging unmet
need that will progressively overcome every other trad-
itional debate. In this regard, the efficacy of current
Fig. 1 HGSOC treatment options according to ESMO and NCCN recommendations in front line a and recurrent b clinical settings
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available treatments measured by progression or relapse
rate is represented in Fig. 2.
The standard of care for newly diagnosed HGSOC pa-
tients consists of primary debulking surgery (PDS) and
platinum-based chemotherapy. The amount of residual
disease after surgery remains a key prognostic variable
supporting the role of PDS with maximal debulking of
tumour [13, 14]. Although desirable, optimal or subopti-
mal (less than 1 cm in maximum diameter of residual
tumour) surgeries are only achieved in 25–40% of cases
undergoing PDS worldwide [15]. Thus, neoadjuvant
chemotherapy (NACT) followed by interval debulking
surgery (IDS) has been tested as an alternative option.
At least four randomized controlled trials were con-
ducted to compare NACT versus PDS in the past years.
Although debates on this topic continue, NACT has be-
come an established practice of care in patients with
high tumor load or severe comorbidities [16–19].
The combination of carboplatin and paclitaxel is the
‘backbone’ of the chemotherapeutic treatment for ad-
vanced HGSOC [20–22]. While most HGSOC patients
show a good response to the conventional platinum-
based chemotherapy, ~ 15% of women experience
primary resistance to these treatments [20–24]. To date,
there are no validated predictive markers of primary
platinum refractory or resistant disease. Although limited
and biologically unfounded, the time since the last platinum
chemotherapy currently defines resistance (≤ 6months) or
sensitivity (> 6months) to the treatment in HGSOC pa-
tients that experience recurrent disease [25, 26].
Subsequent randomized trials have been designed
adding a third drug, either in combination or in main-
tenance. These trials lead to the approval of Bevacizu-
mab and two types of poly-ADP-ribose polymerase
(PARP) inhibitors (Olaparib and Niraparib) [26–29].
Bevacizumab is a humanized monoclonal antibody
against vascular endothelial growth factor A (VEGF-A).
Unfortunately, no molecular biomarkers can faithfully
predict its benefit in patients. Indeed, neither angiogenic
markers (i.e. CD31, microvessel density and tumor
VEGF-A levels) nor predictive signatures based on com-
binations of biomarkers (i.e. mesothelin, FLT4, alpha-1
acid glycoprotein and CA125 or Ang1 and Tie2) were
prospectively validated in large clinical trials and, there-
fore, were not introduced into clinical practice [30, 31].
Currently, only clinical biomarkers, including stage,
Fig. 2 Efficacy of the currently available treatments in HGSOC. Data are expressed as the median rate of freedom from disease progression and
from death at a certain interval time
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debulking status, residual tumor and presence of ascites,
are used to select patients for first line treatment with
Bevacizumab. Olaparib and Niraparib are inhibitors of
the PARP-1 and -2 enzymes and are able to selectively
kill cancer cells that are defective for the BRCA 1 and 2
tumor suppressors. PARP1/2, like BRCA1/2, are in-
volved in the DNA damage response pathway that pro-
motes homologous recombination (HR) and repair of
the DNA lesions. Thus, concomitant inhibition of this
pathway by BRCA1/2 mutations and PARP inhibitors
(PARPi) results in synthetic lethality of cancer cells [32,
33]. However, although mutations in BRCA1/2 genes
represent the strongest hallmark of sensitivity to PARPi,
up to 40% of HGSOC patients bearing these mutations
fail to respond to treatment [32]. On the other hand, tu-
mors harboring other mutations that impair the HR
pathway exhibited remarkable responses to PARPi [32–
35]. Thus, direct evaluation of HR proficiency may help
stratify more accurately the HGSOC patients who would
benefit of treatment with PARPi. However, current as-
says of HR proficiency are believed to be unsuitable to
exclude patients from PARPi therapy, at least in second
line platinum sensitive relapse, in which platinum sensi-
tivity is still considered the best predictor of response to
PARPi [11]. The evaluation of genome-wide loss of het-
erozygosity (LOH) or genomics scars (a score based on
telomeric imbalance, LOH and large-scale rearrange-
ments) could indirectly assess HR deficiency status,
including also patients whose tumors harbor HR-
impairing mutations different from those in the BRCA1/
2 genes. However, attempts to use these tests as predict-
ive markers in the maintenance setting were not com-
pletely successful and the tests were not conclusive in
up to 20% of patients due to technical issues [36, 37].
Moreover, reversion of HR deficiency, which may occur
upon development of resistance to platinum and to
PARPi and likely contributes to clinical drug resistance,
is a major limitation of current HR assays [38, 39].
Overall, targeted therapies produced a paradigm shift
in the treatment of HGSOC, transforming it into a
chronic condition. Up to 80% of HGSOC patients re-
lapses within 24months and treatment options at that
time are also conditioned by first line treatments [40].
The best treatment sequence or combination challenges
clinicians as much as the optimal selection of patients
for each treatment. Differently from Bevacizumab whose
efficacy beyond progression has been clearly reported, it
is at present unclear whether PARPi maintain efficacy in
a second treatment and if they can be used also in
patients who have previously received PARPi [41, 42].
Drugs under investigation
Most ongoing clinical trials for HGSOC are focused on
immune check point inhibitors which are mainly based
on inhibiting the PD-1/PD-L1 pathway. The efficacy of
these agents depends on many factors, including PD-L1
expression, abundance of tumor infiltrating lymphocytes
(TILs), neoantigen load and tumor mutational burden
[43, 44]. Initial over-optimism about these agents in
HGSOC treatment has been tempered by the disap-
pointing results emerged in clinical trials [45–50].
In particular, in recurrent patients, immune check
point inhibitors failed to demonstrate any relevant bene-
fit both as single agent (KEYNOTE-100, single arm trial
on Pembrolizumab) and in combination with chemo-
therapy (JAVELIN 200, randomized trial pegylated lipo-
somal doxorubicin and Avelumab vs pegylated liposomal
doxorubicin single agent vs Avelumab single agent; MK-
3475, single arm trial on Pembrolizumab in combination
with weekly paclitaxel) or with antiangiogenetic agents
(NCT02873962, single arm on the combination of anti-
PD1 Nivolumab with Bevacizumab) [46, 47, 49]. Clinical
results were disappointing also in newly diagnosed pa-
tients. Indeed, the JAVELIN 100 phase III randomized
trial, which tested Avelumab combined with platinum-
based chemotherapy and as maintenance vs chemother-
apy alone, was prematurely terminated for futility at the
pre-planned interim analysis [48]. Likewise, the combin-
ation of Atezolizumab/Bevacizumab failed to demon-
strate an improvement in progression free survival with
respect to Bevacizumab alone in newly diagnosed
HGSOC patients in the recently presented IMAGYN050
trial [50].
The combination of immune check point inhibitors
with PARPi is supported by a strong rationale. In-
deed, HR deficient (HRD) tumors are characterized
by elevated PD-L1 expression and persistence of non-
lethal DNA defects, which continuously stimulate in-
nate immune cells to release pro-inflammatory sub-
stances. This tumor microenvironment probably
induces the switch from a Th1-mediated immunity to
chronic inflammation and immunosuppression [51].
PARPi, by triggering catastrophic DNA damage, espe-
cially in HRD cells, could restore a productive Th1
immune response and reset the tumor microenviron-
ment [52]. In line with this hypothesis, it was re-
ported that in mouse models bearing mutations in
the Brca1/2 genes, PARPi increased the mutational
tumor load, promoted the recruitment of TILs and
activated the interferon-mediated pathway by syner-
gizing with immune check point inhibitors [52].
Lastly, the redundant nature of immune control and
the cross talk between signaling pathways strongly sup-
port the blockade of multiple immune checkpoints as a
strategy to improve the efficacy of anti-PD1-PDL1 ther-
apy and to overcome resistance [53]. On this basis, many
clinical trials are currently verifying both hypotheses in
first line and recurrent clinical settings [54–62].
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Patient-derived organoids
Human organoids are stem cell-derived three-
dimensional (3D) culture systems exhibiting interesting
perspectives in both basic and translational research [6,
63, 64]. Organoid cultures have been generated from al-
most all endoderm-derived tissues and were demon-
strated to faithfully recapitulate the features of the tissue
of origin [63]. Furthermore, these 3D cultures can also
be used to propagate tumor tissues, thus providing an
in vitro model for the study of human cancers [6, 64].
Tumor organoid lines have been obtained from many
types of epithelial cancers, such as lung, esophageal,
bladder, endometrial, ovarian, renal, colorectal, gastro-
intestinal, pancreatic, prostate, breast and liver cancer [6,
63, 64], and were also recently cultured from glioblast-
oma tissues [65, 66].
An important feature of PDOs is that they recapitulate
the cellular heterogeneity that characterizes the tumor
from which they are derived, thus allowing high quality
modeling of human carcinogenesis [6, 63, 64]. PDOs can
be expanded for long-term, cryopreserved in biobanks
and efficiently recovered after thawing [6, 63–66]. Fur-
thermore, the relatively simple culture conditions and
limited costs required to maintain them, make PDOs ex-
cellent models also for in vitro drug screening [6]. In-
deed, several studies in the past three years have clearly
shown that drug responses in PDOs summarize patient’s
responses in the clinic [6, 63–66].
The success rate of initiation, time of establishment,
ease of maintenance and growth rates of PDOs vary con-
siderably, depending on the type of cancer and on the
percentage of proliferating cells in the specific biopsy.
Nevertheless, once established the PDOs display several
advantages with respect to other cancer model systems.
Compared to the classical 2D cancer cell lines, organoids
are more difficult to operate and more expensive to
maintain. However, they represent more reliably the
pathological features of the tumor, as PDOs maintain
genetic stability and tumor heterogeneity [6, 8–10, 67–
74], which instead are lost during the long-term
selection required to establish 2D tumor cell lines. In
comparison with patient-derived xenografts (PDXs) or
genetically engineered animal models, PDOs are less
time consuming, less expensive and more appropriate
for high-throughput drug screening. Furthermore, PDOs
are usually obtained with higher success rate than PDXs
and can also be formed from non-transformed cell cul-
tures or preinvasive cancer models [6, 8–10, 67–74].
Lastly, with respect to spheroids, which are clusters of
proliferating cells that assemble in 3D sphere-like struc-
tures floating in the culture medium [75], PDOs offer a
better representation of the architecture of the tumor, as
they assemble onto a reconstituted matrix that resem-
bles the basal lamina of epithelia and recapitulate the
cellular heterogeneity of the tumor mass. Nevertheless,
one limitation of PDOs is currently represented by the
lack of reliable protocols capable to faithfully reproduce
the tumor microenvironment, which comprises the
stroma, immune cells and blood vessels [6, 8–10, 67–
74]. However, the recent development of organoids
cocultured with tumor microenvironment components
holds promise for the possibility to evaluate complex
features of tumors in the near future [76, 77]. Short term
PDO cultures were recently shown to maintain tumor
infiltrating immune cells and have been successfully
employed for comparative analyses of immune check-
point therapies responses [77]. Moreover, in cancers
characterized by a high tumor mutational burden, co-
culture of PDOs with peripheral blood lymphocytes gen-
erated CD8+ T cell clones specifically reactive against
neoplastic cells, thus potentially valuable for adoptive
cell transplantation [78]. Another current limitation to
application of PDO platforms to clinical trials is the rela-
tively limited information regarding their predictive
value in terms of response to treatments. Nevertheless,
eighteen clinical trials including various cancer types are
currently evaluating this issue, by testing the consistency
and accuracy of PDOs to predict the clinical efficacy of





NCT03500068, NCT04278326, NCT03890614). These
issues are crucial because, in spite of the great improve-
ment that PDOs have brought to preclinical cancer re-
search, several challenges still need to be addressed
before they can exert a concrete impact in clinical ad-
vance. For instance, validation of short-term organoids
as tools that faithfully mimic the tumor microenviron-
ment elements (i.e. fibroblasts, immune cells, vascular
populations) is necessary in order to use PDOs as accur-
ate platform for high-throughput drug and immunother-
apy screens on single patients’ cancer sample.
Furthermore, reliability of the drug response of PDOs as
prognostic factor needs to be evaluated on large cohorts
before it can enter in clinical routine at single patient
level. It is conceivable that once these limitations are
overcome, PDOs will be routinely used for a new gener-
ation of personalized clinical trials.
Ovarian cancer PDOs
To investigate the state of the art in the research
employing PDOs from OC tissues, we carried out a sys-
tematic review and meta-analysis (PRISMA) of the lit-
erature indexed in PubMed, MEDLINE and EMBASE
electronic databases using the following terms: ‘orga-
noids’ AND ‘ovarian cancer’. All types of articles were
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included, with the exception of case reports and com-
mentaries or studies that did not fully report clinical and
technical data on organoids features, establishment and
maintenance (see the consort diagram represented in
Fig. 3).
Several protocols to obtain PDO cultures from OC
have been reported in the past three years [6, 8–10, 67–
74]. The main experimental conditions and key findings
of these studies are summarized in Table 1. Overall, the
published data indicate the efficient derivation (success
rate, ranging from 60 to > 90%) of a wide variety of OC
subtypes (high grade and low grade serous carcinoma,
carcinosarcoma, clear cell carcinoma, endometrioid car-
cinoma, mucinous and serous borderline tumor, malig-
nant Brenner tumor) [69]. The timing required for the
establishment of OC PDOs in culture varied significantly
between cases, ranging from one to four weeks [6, 8–10,
67–74]. Importantly, it was possible to obtain PDOs
from both the primary tumor and the metastatic lesions,
therefore deriving multiple organoid lines from individ-
ual patients, a strategy that allows to also address the
heterogeneity of the tumor.
A key feature of OC PDOs is to maintain the main
hallmarks of the original tumor, including histological
characteristics, biomarker expression, genomic profile
and tumor heterogeneity [6, 8–10, 67–74]. In particular,
OC PDOs were shown to faithfully recapitulate the gen-
omic landscape of the original tumor and to be exploit-
able for functional profiling of DNA repair efficiency
and response to therapeutic drugs. Indeed, when it was
compared to the response of the patient, PDOs generally
demonstrated similar features [6, 8–10, 67–74]. For in-
stance, the HRD mutational signature of the PDO could
predict sensitivity of both the organoid and the primary
tumor to treatment with PARPi [8, 10]. Moreover, OC
PDOs were successfully used to directly test HR profi-
ciency by biological assays and this parameter was also
in line with the sensitivity of the organoid to PARPi [9].
This observation suggests that OC PDOs could be used
to assess the HRD status independently of the muta-
tional signature, thus potentially uncovering also defects
in genes and pathway not yet associated with HR.
Recent development in the organoid field have yielded
culture conditions that allow long-term expansion of
OC PDOs through slight modifications of the medium
and growth factors utilized [70]. Together with the dem-
onstration that OC PDOs can be cryopreserved [9, 70,
74], these results suggest that it will be possible to estab-
lish stable biobanks of PDOs with highly detailed fea-
tures, to match the wide heterogeneity in tumor features
that clinicians currently face. Such biobanks could be
potentially employed for parallel screening of new drugs
Fig. 3 Consort Diagram
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or drug combinations in a multicenter setting, thus fa-
voring the employment of OC PDOs in clinical trials.
Three clinical trials are currently ongoing to evaluate
the role of PDOs in predicting the clinical efficacy of anti-
cancer drugs in OC (NCT04279509, NCT04768270 and
NCT04555473). The NCT04279509 trial is a single-centre
study aimed at prospectively determine if high-throughput
drug screen assays using PDOs can accurately select che-
motherapeutic agents that result in objective response in
patients with refractory solid tumours (head and neck
squamous cell carcinoma, colorectal, breast and epithelial
OC). NCT04768270 is a single-centre study aimed at ver-
ify whether PDOs can help guide precision treatments for
OC patients. NCT04555473 is a longitudinal observational
phase II study of the reliability of HGSOC PDOs as model
for the patients’ response to treatments and it is con-
ducted by our group. In this latter trial, PDOs are being
established from both PDS and IDS cases preceded by
NACT. Since organoids represent a model system com-
parable to PDXs, we tested the null hypothesis that the
possibility of correctly identifying the drug-sensitivity
could improve from 80% (as assessed by xenografts) to at
least 95%. The first step was planned to include 7 patients;
if 5 or more PDOs fail in the correct identification of
drug-sensitivity compared to patients’ response, the trial
will be terminated. If the trial proceeds to the second
stage, a total of 43 patients will be studied. Considering a
patient dropout of approximately 10%, the study was
planned to enroll a minimum of 48 patients (see Fig. 4).
Conclusions
HGSOC remains a devastating cancer for which new
therapeutic strategies are urgently needed. In this sce-
nario, PDOs represent reliable experimental models
that can address several clinical challenges. However,
current major bottlenecks regarding their use to sup-
port clinical decisions are related to efficacy, time,
costs and accuracy in mimicking the overall cancer
complexity.
In order to increase the efficacy, it will be crucial
to standardize the procedures of tissue manipulation,
the media and the growth factors required for each
type of PDO. Such standardize guidelines would re-
duce the need of specialist skills and might promote
the widespread usage of this technology in clinical
settings. Major limits to significantly decrease the
time for PDOs outgrowth are related to the quality of
the biopsy. In particular, the possibility of having
tissue fragments of sufficient size and enriched in
proliferating cancer cells from laparoscopic biopsies
or ultrasound guided biopsy would allow higher effi-
ciency of PDO formation also from these surgical in-
terventions. Costs will likely drop as technologies
mature and protocols become standardized. However,
median costs for PDO generation and maintenance
are relatively high at the moment, thus representing a
potential limitation for their application to routine
management of patients. Lastly, the most limiting as-
pect of currently available PDOs is represented by the
Fig. 4 NCT04555473 trial design
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lack of tumor microenvironment. Large efforts are
ongoing to include stromal, immune and vascular
cells in these cultures, thus to represent more faith-
fully the disease. This is particularly relevant for
HGSOC, where several targeted therapies involve im-
mune checkpoints and angiogenic inhibitors. Never-
theless, mimicking the whole microenvironment
characterizing the tumor is challenging, especially
with respect to vascularization of the PDO. Improve-
ment in these procedures will likely require substan-
tial time and costs before the best and most
reproducible conditions are set up.
PDOs will certainly serve as a complement to other
traditional models to study cancer, such as primary
human tissues and animal models, which are cur-
rently the gold standard in biomedical research. How-
ever, once PDOs are improved and optimized, they
may have unique characteristics to be introduced in
future clinical trials as empirical predictor of patients’
response to therapies (see Fig. 5).
Abbreviations
PDOs: Patients derived organoids; OC: Ovarian cancer; HGSOC: High grade
serous ovarian cancer; PDS: Primary debulking surgery; IDS: Interval
debulking surgery; NACT: Neoadjuvant chemotherapy; PDX: Patient-derived
xenograft; LOH: Loss of heterozygosis; PARPi: Poly ADP ribose polymerase
inhibitors; HRD: Homologous recombination deficiency; HR: Homologous
recombination; PD-1: Programmed cell death protein 1; PD-L1: Programmed
cell death protein 1 ligand; TILs: Tumor infiltrating lymphocytes; VEGF-
A: Vascular endothelial growth factor A; 3D: Three-dimensional
Acknowledgements
This work is partially supported by grants from Associazione Italiana Ricerca
sul Cancro (AIRC IG23416) and Italian Ministry of Health (GR-2019-12371435).
Authors’ contributions
CN, GV, GD, EC, ML and DL performed the literature search. CN, GV and CS
analyzed selected papers. EC, ML and CN realized Figures and Tables. CN, GV
and DL were dedicated to Writing and Original Draft Preparation. GS and CS
supervised the whole process. All authors read and approved the final
manuscript.
Funding
This work is partially supported by grants from Associazione Italiana Ricerca
sul Cancro (AIRC IG23416) and Italian Ministry of Health (GR-2019-12371435).
Availability of data and materials
Not applicable.
Declarations





- C. Nero, G. Vizzielli, C. Sette, E. Cesari, M. Loverro have no conflict of interest
to declare.
- G. Daniele has served on advisory board of Beigene and received support
for travel and accomodation from Roche.
- G Scambia has served on advisory boards for TESARO Bio Italy S.r.l,
Johnson & Johnson, Clovis Oncology Italy S.r.l. He received support.
for travel or accommodation from MSD Italy S.r.l and Clovis.
Oncology Italy S.r.l, and institutional research funding from MSD Italy S.r.l.
- D. Lorusso has served on advisory boards for Clovis Oncology,
AstraZeneca, Genmab/Seattle Genetics, MSD, ImmunoGen,
Fig. 5 PDOs based future clinical trials
Nero et al. Journal of Experimental & Clinical Cancer Research          (2021) 40:116 Page 11 of 14
PharmaMar, Roche, and Tesaro/GSK, received support for travel or.
accommodation from AstraZeneca, GSK and Roche and institutional.
research funding from Merck, GSK, Clovis, Pharmamar.
Author details
1Fondazione Policlinico Universitario A. Gemelli IRCCS, L.go Agostino gemelli,
8, 00168 Roma, Italy. 2Dipartimento di Scienze della vita e sanità pubblica,
Università Cattolica del Sacro Cuore, Roma, Italy. 3Dipartimento di
Neuroscienze, Sezione di Anatomia Umana, Università Cattolica del Sacro
Cuore, Roma, Italy.
Received: 3 February 2021 Accepted: 17 March 2021
References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer
statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide
for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
https://doi.org/10.3322/caac.21492.
2. Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY.
Ovarian cancer. Nat Rev Dis Primers. 2016;2(1):16061. https://doi.org/10.103
8/nrdp.2016.61.
3. Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E,
et al. Standard chemotherapy with or without bevacizumab for women
with newly di- agnosed ovarian cancer (ICON7): overall survival results of a
phase 3 randomised trial. Lancet Oncol. 2015;16:928–36 https://doi.org/10.1
016/S1470-2045(15)00086-8.
4. Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M,
Balmaña J, et al. Olaparib monotherapy in patients with advanced cancer
and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33(3):244–50. https://
doi.org/10.1200/JCO.2014.56.2728.
5. van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder
HWR, Hermans RHM, de Hingh IHJT, van der Velden J, Arts HJ, Massuger
LFAG, Aalbers AGJ, Verwaal VJ, Kieffer JM, Van de Vijver KK, van Tinteren H,
Aaronson NK, Sonke GS. Hyperthermic Intraperitoneal Chemotherapy in
Ovarian Cancer. N Engl J Med. 2018; 378(3): 230–240. doi: https://doi.org/1
0.1056/NEJMoa1708618. PMID: 29342393.
6. Tuveson D, Clevers H., Cancer modeling meets human organoid
technology. Science. 2019; 364(6444): 952–955. doi: https://doi.org/10.1126/
science.aaw6985. PMID: 31171691.
7. Lõhmussaar K, Boretto M, Clevers H. Human-derived model Systems in
Gynecological Cancer Research. Trends Cancer 2020;6(12):1031–1043.
doi: https://doi.org/10.1016/j.trecan.2020.07.007. Epub 2020 Aug 24.
PMID: 32855097
8. Hill SJ, Decker B, Roberts EA, Horowitz NS, Muto MG, Worley MJ, et al.
Prediction of DNA repair inhibitor response in short-term patient-derived
ovarian Cancer Organoids. Cancer Discov. 2018;8:1404–21.
9. Kopper O, DeWitte CJ, Lõhmussaar K, ValleInclan JE, Hami N, Kester L, et al.
An organoid platform for ovarian cancer captures intra- and interpatient
heterogeneity. Nat Med. 2019;25:838–49.
10. de Witte CJ, Espejo Valle-Inclan J, Hami N, Lõhmussaar K, Kopper O, Vreuls
CPH, et al. Patient-derived ovarian Cancer Organoids mimic clinical
response and exhibit heterogeneous inter- and Intrapatient drug responses.
Cell Rep. 2020;31(11):107762. https://doi.org/10.1016/j.celrep.2020.107762.
11. Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I,
Morice P, Pignata S, Ray-Coquard I, Vergote I, Baert T, Belaroussi I, Dashora
A, Olbrecht S, Planchamp F, Querleu D; ESMO-ESGO ovarian Cancer
consensus conference working group. ESMO-ESGO consensus conference
recommendations on ovarian cancer: pathology and molecular biology,
early and advanced stages, borderline tumours and recurrent disease†. Ann
Oncol 2019;30(5):672–705. doi: https://doi.org/10.1093/annonc/mdz062.
PMID: 31046081.
12. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Ovarian
Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer
Version 1. 2020 — March 11, 2020.
13. Polterauer S, Vergote I, Concin N, et al. Prognostic Value of Residual Tumor
Size in Patients With Epithelial Ovarian Cancer FIGO Stages IIa-IV: analysis of
the OVCaD Data. Int J Gynecol Cancer. 2012;22:380–5. https://doi.org/10.1
097/IGC.0b013e31823de6ae.
14. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal
cytoreductive surgery for advanced ovarian carcinoma during the platinum
era: a meta-analysis. J Clin Oncol. 2002;20:1248–59. https://doi.org/10.1200/
JCO.20.5.1248.
15. Dauplat J, Le Bouedec G, Pomel C, Scherer C. Cytoreductive surgery for
advanced stages of ovarian cancer. Semin Surg Oncol. 2000;19:42e8.
16. Vergote I, Trope' CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al.
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian
cancer. N Engl J Med. 2010;363:943e53.
17. Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary
chemotherapy versus primary surgery for newly diagnosed advanced
ovarian cancer (CHORUS): an openlabel, randomised, controlled, non-
inferiority trial. Lancet. 2015;386:249e57.
18. Onda T, Matsumoto K, Shibata T, Sato A, Fukuda H, Konishi I, et al. Phase III
trial of upfront debulking surgery versus neoadjuvant chemotherapy for
stage III/IV ovarian, tubal and peritoneal cancers: Japan clinical oncology
group study JCOG0602. Jpn J Clin Oncol. 2008;38:74e7.
19. Fagotti A, Ferrandina G, Vizzielli G, Fanfani F, Gallotta V, Chiantera V,
Costantini B, Margariti PA, Gueli Alletti S, Cosentino F, Tortorella L, Scambia
G. Phase III randomised clinical trial comparing primary surgery versus
neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high
tumour load (SCORPION trial): final analysis of peri-operative outcome. Eur J
Cancer 2016;59:22–33. doi: https://doi.org/10.1016/j.ejca.2016.01.017. Epub
2016 Mar 19. PMID: 26998845.
20. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA,
Mannel RS, DeGeest K, Hartenbach EM, Baergen R; Gynecologic oncology
group. Phase III trial of carboplatin and paclitaxel compared with cisplatin
and paclitaxel in patients with optimally resected stage III ovarian cancer: a
gynecologic oncology group study. J Clin Oncol 2003;21(17):3194–3200. doi:
https://doi.org/10.1200/JCO.2003.02.153. Epub 2003 Jul 14. PMID: 12860964.
21. du Bois A, Lück HJ, Meier W, Adams HP, Möbus V, Costa S, Bauknecht T,
Richter B, Warm M, Schröder W, Olbricht S, Nitz U, Jackisch C, Emons G,
Wagner U, Kuhn W, Pfisterer J; Arbeitsgemeinschaft Gynäkologische
Onkologie ovarian Cancer study group. A randomized clinical trial of
cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of
ovarian cancer. J Natl Cancer Inst 2003;95(17):1320–1329. doi: https://doi.
org/10.1093/jnci/djg036. PMID: 12953086.
22. International Collaborative Ovarian Neoplasm Group. Paclitaxel plus
carboplatin versus standard chemotherapy with either single-agent
carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women
with ovarian cancer: the ICON3 randomised trial. Lancet. 2002; 360(9332):
505–515. doi: https://doi.org/10.1016/S0140-6736(02)09738-6. Erratum in:
Lancet. 2003 Feb 22;361(9358):706. PMID: 12241653.
23. Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E, Aoki
D, Jobo T, Kodama S, Terauchi F, Sugiyama T, Ochiai K; Japanese
Gynecologic Oncology Group. Long-term results of dose-dense paclitaxel
and carboplatin versus conventional paclitaxel and carboplatin for
treatment of advanced epithelial ovarian, fallopian tube, or primary
peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.
Lancet Oncol. 2013; 14(10):1020–1026. doi: https://doi.org/10.1016/S1470-2
045(13)70363-2. Epub 2013 Aug 13. PMID: 23948349.
24. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen
GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A,
Tropé C; ICON and AGO collaborators. Paclitaxel plus platinum-based
chemotherapy versus conventional platinum-based chemotherapy in
women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.
Lancet. 2003;361(9375):2099–2106. doi: https://doi.org/10.1016/s0140-673
6(03)13718-x. PMID: 12826431.
25. Friedlander M, Trimble E, Tinker A, Alberts D, Avall-Lundqvist E, Brady M,
et al. Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer. 2011;
21(4):771–5. https://doi.org/10.1097/IGC.0b013e31821bb8aa.
26. Stuart G., Kitchener H., Bacon M., Dubois A., Friedlander M., Ledermann J.,
et al. . (2011) 2010. Gynecologic Cancer intergroup (GCIG) consensus
statement on clinical trials in ovarian cancer: report from the fourth ovarian
Cancer consensus conference. Int J Gynecol Cancer 21: 750–755.
27. Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E,
Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly
F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM,
Farrelly L, Kaplan R, Parmar MK, Perren TJ; ICON7 trial investigatorsStandard
chemotherapy with or without bevacizumab for women with newly
diagnosed ovarian cancer (ICON7): overall survival results of a phase 3
randomised trial. Lancet Oncol. 2015; 16(8): 928–936. doi: https://doi.org/1
0.1016/S1470-2045(15)00086-8. Epub 2015 Jun 23.PMID: 26115797.
Nero et al. Journal of Experimental & Clinical Cancer Research          (2021) 40:116 Page 12 of 14
28. González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill
W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K,
Jardon K, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Lund B,
Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Pérez MJ, Shahin MS,
Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D,
Monk BJ; PRIMA/ENGOTOV26/ GOG-3012 Investigators. Niraparib in
Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J
Med. 2019; 381(25): 2391–2402. doi: https://doi.org/10.1056/NEJMoa191
0962. Epub 2019 Sep 28. PMID: 31562799.
29. Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M,
Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A,
González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES,
Bloomfield R, DiSilvestro P. Maintenance Olaparib in patients with newly
diagnosed advanced ovarian Cancer. N Engl J Med 2018 Dec 27;379(26):
2495–2505. doi: https://doi.org/10.1056/NEJMoa1810858. Epub 2018 Oct 21.
PMID: 30345884.
30. Collinson F, Hutchinson M, Craven RA, et al. Predicting response to
bevacizumab in ovarian cancer: a panel of potential biomarkers informing
treatment selection. Clin Cancer Res. 2013;19(18):5227–39. https://doi.org/1
0.1158/1078-0432.CCR-13-0489.
31. Backen A, Renehan AG, Clamp AR, et al. The combination of circulating
Ang1 and Tie2 levels predicts progression-free survival advantage in
bevacizumab-treated patients with ovarian cancer. Clin Cancer Res. 2014;
20(17):4549–58. https://doi.org/10.1158/1078-0432.CCR-13-3248.
32. Audeh MW, Carmichael J, Penson RT, et al. Oral poly (ADP-ribose)
polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations
and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;
376(9737):245–51. https://doi.org/10.1016/S0140-6736(10)60893-8.
33. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with
recurrent high-grade serous or poorly differentiated ovarian carcinoma or
triple-negative breast cancer: a phase 2, multicentre, open-label, non-
randomised study. Lancet Oncol. 2011;12(9):852–61. https://doi.org/10.1016/
S1470-2045(11)70214-5.
34. Fong PC, Yap TA, Boss DS, et al. Poly (ADP)-ribose polymerase inhibition:
frequent durable responses in BRCA carrier ovarian cancer correlating with
platinum-free interval. J Clin Oncol. 2010;28(15):2512–9. https://doi.org/10.12
00/JCO.2009.26.9589.
35. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA
damage by homologous recombination and sensitivity to poly (ADP-ribose)
polymerase inhibition. Cancer Res. 2006;66(16):8109–15. https://doi.org/10.11
58/0008-5472.CAN-06-0140.
36. Coleman RL, Swisher EM, Oza AM, Scott CL, Giordano H, Lin KK, et al.
McNeishRefinement of prespecified cutoff for genomic loss of
heterozygosity (LOH) in ARIEL2 part 1: A phase II study of rucaparib in
patients (pts) with high grade ovarian carcinoma (HGOC). J Clin Oncol.
2016;34(15_suppl):5540.
37. Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D’Andrea AD. Homologous
recombination deficiency: exploiting the fundamental vulnerability of
ovarian cancer. Cancer Discov. 2015;5(11):1137–54. https://doi.org/10.11
58/2159-8290.CD-15-0714.
38. Norquist B, Wurz KA, Pennil CC, Garcia R, Gross J, Sakai W, et al. Secondary
somatic mutations restoring BRCA1/2 predict chemotherapy resistance in
hereditary ovarian carcinomas. J Clin Oncol. 2011;29(22):3008–15. https://doi.
org/10.1200/JCO.2010.34.2980.
39. Quigley D, Alumkal JJ, Wyatt AW, Kothari V, Foye A, Lloyd P, et al. Analysis
of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2
Reversion Mutations Associated with Resistance to PARP Inhibitors. Cancer
Discov. 2017;7(9):999–1005. https://doi.org/10.1158/2159-8290.CD-17-0146.
40. Luvero D, Milani A, Ledermann JA. Treatment options in recurrent ovarian
cancer: latest evidence and clinical potential. Ther Adv Med Oncol. 2014;
6(5): 229–239. doi: https://doi.org/10.1177/1758834014544121. PMID:
25342990; PMCID: PMC4206613.
41. Robert L. Coleman, Mark F. Brady, Thomas J Herzog, Deborah Kay Armstrong,
Paul Sabbatini, Joan L. Walker, Byoung Kim, Keiichi Fujiwara, Krishnansu Sujata
Tewari, David M. O'Malley. Bevacizumab after bevacizumab in platinum-
sensitive recurrent ovarian cancer: A subgroup analysis of GOG0213. J Clin
Oncol. DOI: https://doi.org/10.1200/JCO.2016.34.15_suppl.5523 Journal of
Clinical Oncology 34, no. 15_suppl (2016) 5523.
42. https://clinicaltrials.gov/ct2/show/NCT03106987
43. Wu Y, Chen W, Xu ZP, Gu W. PD-L1 Distribution and Perspective for Cancer
Immunotherapy-Blockade, Knockdown, or Inhibition. Front Immunol. 2019;
10: 2022. doi: https://doi.org/10.3389/fimmu.2019.02022. PMID: 31507611;
PMCID: PMC6718566.
44. Spranger S, Gajewski TF. Impact of oncogenic pathways on evasion
of antitumour immune responses. Nat Rev Cancer. 2018;18(3):139–47.
https://doi.org/10.1038/nrc.2017.117. Epub 2018 Jan 12.
45. Matulonis UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S,
Vergote I, et al. Antitumor activity and safety of pembrolizumab in patients
with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-
100 study. Ann Oncol. 2019;30(7):1080–7. 31046082. https://doi.org/10.1
093/annonc/mdz135.
46. SGO 2019, Available on line: https://www.cancernetwork.com/view/sgo-
2019-despite-missed-endpoint-javelin-trial-pd-l1-subgroup-analysis-redeems
47. Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant
Ovarian Cancer - Full Text View - https://clinicaltrials.gov/ct2/show/NCT0244
0425.
48. Ledermann JA, Colombo N, Oza M, et al. Avelumab in combination with
and/or following chemotherapy vs chemotherapy alone in patients with
previously untreated epithelial ovarian cancer: Results from the phase 3
javelin ovarian 100 trial. 2020. Society of Gynecologic Oncology Annual
Meeting on Women’s Cancer. LBA 25, Scientific Plenary.
49. Liu JF, Herold C, Gray KP, Penson RT, Horowitz N, Konstantinopoulos PA,
Castro CM, Hill SJ, Curtis J, Luo W, Matulonis UA, Cannistra SA, Dizon DS.
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian
Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019; 5(12): 1731–1738. doi:
https://doi.org/10.1001/jamaoncol.2019.3343. Epub ahead of print. PMID:
31600397; PMCID:PMC6802049.
50. Moore KN, Pignata S. Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39.
A phase III, multicenter, randomized study of atezolizumab versus placebo
administered in combination with paclitaxel, carboplatin, and bevacizumab
to patients with newly diagnosed stage III or stage IV o. Int. J Gynecol
Cancer. 2019;29(2):430–3.
51. Higuchi T, Flies DB, Marjon NA, et al. CTLA-4 blockade synergizes
therapeutically with PARP inhibition in BRCA1-deficient ovarian Cancer.
Cancer Immunol Res. 2015;3(11):1257–68. https://doi.org/10.1158/2326-6066.
CIR-15-0044.
52. Stewart RA, Pilie PG, Yap TA. Development of PARP and immune-
checkpoint inhibitor combinations. Cancer Res. 2018;78(24):6717–25. https://
doi.org/10.1158/0008-5472.CAN-18-2652.
53. Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3--potential
mechanisms of action. Nat Rev Immunol 2015;15(1):45–56. doi: https://doi.
org/10.1038/nri3790. PMID: 25534622.
54. Available on line: https://clinicaltrials.gov/ct2/show/NCT03737643
55. Available on line: https://clinicaltrials.gov/ct2/show/NCT03740165?cond=
ENGOT+OV+43&draw=2&r ank=1.
56. Available on line: https://clinicaltrials.gov/ct2/show/NCT03602859
57. Available on line: https://clinicaltrials.gov/ct2/show/NCT03522246
58. Available on line: https://clinicaltrials.gov/ct2/show/NCT03598270
59. Available on line: https://clinicaltrials.gov/ct2/show/NCT02484404
60. Available on line: https://clinicaltrials.gov/ct2/show/NCT02571725
61. Available on line: https://www.mito-group.it/studi/studio-mito-33-nitche/
62. Addition of a CTLA-4–Targeted Therapy to a Checkpoint Inhibitor in Ovarian
Cancer - The ASCO Post. [https://www.ascopost.com/News/59329].
63. Jihoon Kim, Bon-Kyoung Koo, Juergen A. Knoblich Human organoids:
model systems for human biology and medicine Nat Rev Mol Cell Biol.
2020: 1–14. doi: https://doi.org/10.1038/s41580-020-0259-3 [Epub ahead of
print] PMCID: PMC7339799.
64. Drost J, Clevers H. Organoids in cancer research. Nat Rev Cancer 2018;18(7):
407–418. doi: https://doi.org/10.1038/s41568-018-0007-6. PMID: 29692415.
65. Jacob F, Salinas RD, Zhang DY, Nguyen PTT, Schnoll JG, Wong SZH, Thokala
R, Sheikh S, Saxena D, Prokop S, Liu DA, Qian X, Petrov D, Lucas T, Chen HI,
Dorsey JF, Christian KM, Binder ZA, Nasrallah M, Brem S, O'Rourke DM, Ming
GL, Song H. A Patient-Derived Glioblastoma Organoid Model and Biobank
Recapitulates Inter- and Intra-tumoral Heterogeneity. Cell. 2020; 180(1): 188–
204.e22. doi: https://doi.org/10.1016/j.cell.2019.11.036. Epub 2019 Dec 26.
PMID: 31883794.
66. Zhu Z, Mesci P, Bernatchez JA, Gimple RC, Wang X, Schafer ST,
Wettersten HI, Beck S, Clark AE, Wu Q, Prager BC, Kim LJY, Dhanwani R,
Sharma S, Garancher A, Weis SM, Mack SC, Negraes PD, Trujillo CA,
Penalva LO, Feng J, Lan Z, Zhang R, Wessel AW, Dhawan S, Diamond
MS, Chen CC, Wechsler-Reya RJ, Gage FH, Hu H, Siqueira-Neto JL,
Muotri AR, Cheresh DA, Rich JN. Zika Virus Targets Glioblastoma Stem
Nero et al. Journal of Experimental & Clinical Cancer Research          (2021) 40:116 Page 13 of 14
Cells through a SOX2-Integrin alpha(v)beta(5) Axis. Cell Stem Cell. 2020;
26(2): 187–204.e10. doi: https://doi.org/10.1016/j.stem.2019.11.016. Epub
2020 Jan 16.PMID: 31956038.
67. Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Sboner A, et al.
Personalized in vitro and in vivo Cancer models to guide precision
medicine. Cancer Discov. 2017;7(5):462–77. https://doi.org/10.1158/2159-82
90.CD-16-1154.
68. Phan N, Hong JJ, Tofig B, Mapua M, Elashoff D, Moatamed NA, Huang J,
Memarzadeh S, Damoiseaux R, Soragni A. A simple high-throughput
approach identifies actionable drug sensitivities in patient-derived tumor
organoids. Commun Biol. 2019; 2: 78. doi: https://doi.org/10.1038/s42003-01
9-0305-x. PMID: 30820473; PMCID: PMC6389967.
69. Maru Y, Tanaka N, Itami M, Hippo Y. Efficient use of patient-derived
organoids as a preclinical model for gynecologic tumors. Gynecol Oncol.
2019;154(1):189–98. https://doi.org/10.1016/j.ygyno.2019.05.005. Epub 2019
May 14.
70. Hoffmann K, Berger H, Kulbe H, Thillainadarasan S, Mollenkopf HJ, Zemojtel
T, Taube E, Darb-Esfahani S, Mangler M, Sehouli J, Chekerov R, Braicu EI,
Meyer TF, Kessler M. Stable expansion of high-grade serous ovarian cancer
organoids requires a low-Wnt environment. EMBO J. 2020; 39(6): e104013.
doi: https://doi.org/10.15252/embj.2019104013. Epub 2020 Feb 3. PMID:
32009247; PMCID: PMC7073464.
71. Sun H, Wang H, Wang X, Aoki Y, Wang X, Yang Y, Cheng X, Wang Z, Wang
X. Aurora-A/SOX8/FOXK1 signaling axis promotes chemoresistance via
suppression of cell senescence and induction of glucose metabolism in
ovarian cancer organoids and cells. Theranostics. 2020; 10(15): 6928–6945.
doi: https://doi.org/10.7150/thno.43811. PMID: 32550913; PMCID:
PMC7295065.
72. Nanki Y, Chiyoda T, Hirasawa A, Ookubo A, Itoh M, Ueno M, Akahane T,
Kameyama K, Yamagami W, Kataoka F, Aoki D. Patient-derived ovarian
cancer organoids capture the genomic profiles of primary tumours
applicable for drug sensitivity and resistance testing. Sci Rep. 2020; 10(1):
12581. doi: https://doi.org/10.1038/s41598-020-69488-9. PMID: 32724113;
PMCID: PMC7387538.
73. Chen H, Gotimer K, De Souza C, Tepper CG, Karnezis AN, Leiserowitz GS,
Chien J, Smith LH. Short-term organoid culture for drug sensitivity testing of
high-grade serous carcinoma. Gynecol Oncol 2020;157(3):783–792. doi:
https://doi.org/10.1016/j.ygyno.2020.03.026. Epub 2020 Apr 4. PMID:
32253045.
74. Maenhoudt N, Defraye C, Boretto M, Jan Z, Heremans R, Boeckx B, Hermans
F, Arijs I, Cox B, Van Nieuwenhuysen E, Vergote I, Van Rompuy AS,
Lambrechts D, Timmerman D, Vankelecom H. Developing Organoids from
Ovarian Cancer as Experimental and Preclinical Models. Stem Cell Rep. 2020;
14(4): 717–729. doi: https://doi.org/10.1016/j.stemcr.2020.03.004. Epub 2020
Apr 2. PMID: 32243841; PMCID: PMC7160357.
75. Park H, Hwang S, Jeong JY, Jung SG, Choi MC, Joo WD, Song SH, Lee C, An
HJ. Integrative analysis of transcription factors and microRNAs in ovarian
cancer cell spheroids. J Ovarian Res. 2020 ; 13(1): 16. doi: https://doi.org/1
0.1186/s13048-020-00618-7. PMID: 32046751; PMCID: PMC7014770.
76. Neal JT, Li X, Zhu J, Giangarra V, Grzeskowiak CL, Ju J, Liu IH, Chiou SH,
Salahudeen AA, Smith AR, Deutsch BC, Liao L, Zemek AJ, Zhao F, Karlsson K,
Schultz LM, Metzner TJ, Nadauld LD, Tseng YY, Alkhairy S, Oh C, Keskula P,
Mendoza-Villanueva D, De La Vega FM, Kunz PL, Liao JC, Leppert JT,
Sunwoo JB, Sabatti C, Boehm JS, Hahn WC, Zheng GXY, Davis MM, Kuo CJ.
Organoid Modeling of the Tumor Immune Microenvironment. Cell. 2018;
175(7): 1972–1988.e16. doi: https://doi.org/10.1016/j.cell.2018.11.021. PMID:
30550791; PMCID: PMC6656687.
77. Wan C, Keany MP, Dong H, Al-Alem LF, Pandya UM, Lazo S, Boehnke K,
Lynch KN, Xu R, Zarrella DT, Gu S, Cejas P, Lim K, Long HW, Elias KM,
Horowitz NS, Feltmate CM, Muto MG, Worley MJ, Berkowitz RS, Matulonis
UA, Nucci MR, Crum CP, Rueda BR, Brown M, Liu XS, Hill SJ. Enhanced
efficacy of simultaneous PD-1 and PD-L1 immune checkpoint blockade in
high grade serous ovarian cancer. Cancer Res. 2020:canres.1674.2020. doi:
https://doi.org/10.1158/0008-5472.CAN-20-1674. Epub ahead of print. PMID:
33158814.
78. Dijkstra KK, Cattaneo CM, Weeber F, Chalabi M, van de Haar J, Fanchi LF,
Slagter M, van der Velden DL, Kaing S, Kelderman S, van Rooij N, van
Leerdam ME, Depla A, Smit EF, Hartemink KJ, de Groot R, Wolkers MC, Sachs
N, Snaebjornsson P, Monkhorst K, Haanen J, Clevers H, Schumacher TN,
Voest EE. Generation of Tumor-Reactive T Cells by Co-culture of Peripheral
Blood Lymphocytes and Tumor Organoids. Cell. 2018; 174(6): 1586–1598.
e12. doi: https://doi.org/10.1016/j.cell.2018.07.009. Epub 2018 Aug 9. PMID:
30100188; PMCID: PMC6558289.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Nero et al. Journal of Experimental & Clinical Cancer Research          (2021) 40:116 Page 14 of 14
